Alex Bloom is Chief Technical Officer at Aviadobio, a UK Headquartered gene therapy company developing pioneering medicines for neurodegenerative disorders. At Aviado, he is responsible for technical operations, vector development, quality and regulatory affairs. Alex brings nearly 20 years of operational excellence in biologics, with over 15 years spent dedicated to cell and gene therapy development. In this time, Alex has worked on over 25 clinical-stage gene therapy programs. Previously, Alex led regulatory and quality activities at Gyroscope Therapeutics (a Novartis Company) supporting the development of gene therapies and innovative delivery devices for retinal disease. Prior to Gyroscope, Alex held CMC technical leadership and regulatory roles in biotech and mid-size pharma organisation. At Chiesi Farmaceutici, he played a pivotal role in the development and approval of Holoclar®, the first tissue engineered product to be approved in the West. Alex holds a PhD and MSc in molecular biology and biochemistry from Sheffield University, UK.